Abstract
Risk factors for restrictive allograft syndrome (RAS), a severe phenotype of chronic lung allograft dysfunction after lung transplantation, are currently not well known. In this retrospective nested case-control-study, we analyzed 69 RAS patients and 69 matched non-CLAD controls to identify clinical risk factors for RAS. RAS patients demonstrated overall higher blood eosinophils (p=0.02), increased bronchoalveolar eosinophils (p<0.001) and lymphocytes (p=0.03), and a higher incidence of infections, particularly Pseudomonas (p=0.003), invasive fungal disease (p<0.001, mainly Aspergillus species), SARS-CoV-2 (p<0.001) and CMV (p=0.04), compared to non-CLAD controls. Anti-HLA antibodies, especially persistent donor-specific antibodies (p<0.001), especially targeting HLA-DQ and HLA-DR loci, and antibody-mediated rejection (p<0.001), were strongly associated with later RAS. Histopathological lung injury patterns on transbronchial biopsy (p<0.001), and persistent chest CT opacities in absence of pulmonary dysfunction (p<0.001) were identified as early indicators of later RAS. Proactive detection and management of these risk factors could help mitigate future decline in allograft function, and reduce progression to clinical RAS. Future studies should explore early treatment strategies targeting these modifiable factors to preserve allograft function and improve long-term outcomes for lung transplant recipients.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call